Revenue up 22% as MannKind (NASDAQ: MNKD) absorbs Furoscix deal costs
Rhea-AI Filing Summary
MannKind Corporation reported strong top-line growth for the fourth quarter and full year 2025, driven by its cardiometabolic and inhaled therapies portfolio. Q4 2025 revenues were $111.9 million, up 46% from Q4 2024, with full year 2025 revenues of $349.0 million, a 22% increase over 2024.
Growth came from higher royalties on Tyvaso DPI, increased collaborations and services for United Therapeutics, and rising Afrezza sales, plus $23.2 million of Furoscix revenue added after acquiring scPharmaceuticals in October 2025. Despite this, MannKind recorded a Q4 2025 net loss of $15.9 million and full year 2025 net income of $5.9 million, down from $27.6 million in 2024, as R&D and SG&A spending rose sharply to support pipeline development and the Furoscix launch.
Positive
- None.
Negative
- None.
Insights
Revenue grew 22% in 2025, but higher spending and deal costs compressed earnings.
MannKind delivered notable top-line expansion, with 2025 revenues of
Profitability, however, moved in the opposite direction. Full year GAAP net income fell to
Non-GAAP results smooth some of these effects: 2025 non-GAAP adjusted net income was
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 26, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1 |
Press release dated February 26, 2026 |
|
|
Exhibit 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MannKind Corporation |
|
|
|
|
|
|
|
Date: February 26, 2026 |
By: |
/s/ David Thomson, Ph.D., J.D. |
|
|
David Thomson, Ph.D., J.D. |
|
|
Corporate Vice President, General Counsel and Secretary |
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Conference call today at 9:00 am ET
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)
a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.
“MannKind closed 2025 with strong momentum across our commercial portfolio and meaningful progress in our pipeline. The addition of Furoscix strengthens our cardiometabolic franchise, while Afrezza and UT-related revenues continue to deliver sustained growth,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “As we enter a catalyst‑rich 2026, with two upcoming FDA decisions, and Nintedanib DPI INFLO-1 Phase 1b topline data, we believe we are well‑positioned to drive long‑term value for patients, providers and shareholders. Our team’s hard work over the last several years is culminating in significant milestones with the potential to drive near-term growth.”
Business Update and Upcoming Milestones
Commercial Products
Furoscix
Afrezza
Development
Nintedanib DPI (MNKD-201)
Other Programs
Corporate Update
Fourth Quarter and Full Year 2025 Financial Results
Revenues
|
|
Three Months |
|
|||||||||||||
|
|
2025 |
|
|
2024 |
|
|
$ Change |
|
|
% Change |
|
||||
Revenues |
|
(Dollars in thousands) |
|
|||||||||||||
Royalties |
|
$ |
33,564 |
|
|
$ |
27,009 |
|
|
$ |
6,555 |
|
|
|
24 |
% |
Collaborations and services |
|
|
27,986 |
|
|
|
26,710 |
|
|
|
1,276 |
|
|
|
5 |
% |
Afrezza |
|
|
22,878 |
|
|
|
18,279 |
|
|
|
4,599 |
|
|
|
25 |
% |
Furoscix(1) |
|
|
23,178 |
|
|
|
— |
|
|
|
23,178 |
|
|
N/A |
|
|
V-Go |
|
|
4,349 |
|
|
|
4,778 |
|
|
|
(429 |
) |
|
|
(9 |
%) |
Total revenues |
|
$ |
111,955 |
|
|
$ |
76,776 |
|
|
$ |
35,179 |
|
|
|
46 |
% |
________________________
|
|
Year |
|
|||||||||||||
|
|
2025 |
|
|
2024 |
|
|
$ Change |
|
|
% Change |
|
||||
Revenues |
|
(Dollars in thousands) |
|
|||||||||||||
Royalties |
|
$ |
128,116 |
|
|
$ |
102,335 |
|
|
$ |
25,781 |
|
|
|
25 |
% |
Collaborations and services |
|
|
106,713 |
|
|
|
100,840 |
|
|
|
5,873 |
|
|
|
6 |
% |
Afrezza |
|
|
74,587 |
|
|
|
64,041 |
|
|
|
10,546 |
|
|
|
16 |
% |
Furoscix(1) |
|
|
23,178 |
|
|
|
— |
|
|
|
23,178 |
|
|
N/A |
|
|
V-Go |
|
|
16,372 |
|
|
|
18,288 |
|
|
|
(1,916 |
) |
|
|
(10 |
%) |
Total revenues |
|
$ |
348,966 |
|
|
$ |
285,504 |
|
|
$ |
63,462 |
|
|
|
22 |
% |
_________________________
Total revenues for the fourth quarter and full year 2025 rose due to increases in revenue from royalties, collaborations and services, and commercial product sales. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI®. Collaborations and services revenue grew due to increased units sold to UT. Revenue from commercial sales increased primarily due to net sales from Furoscix beginning on the scPharma acquisition date of October 7, 2025 as well as an increase in net sales of Afrezza over the prior periods.
Operating Expenses and Other Financial Highlights
Conference Call
MannKind will host a conference call and presentation webcast to discuss these results today at 9:00 a.m. Eastern Time. The webcast will
be accessible via a link on MannKind’s website. A replay will also be available in the same location within 24 hours after the call and accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Forward-Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding MannKind's expectations about 2026 being a catalyst-rich year; the FDA’s potential approval of the sBLA for Afrezza for the pediatric population and of the sNDA for Furoscix ReadyFlow Autoinjector, and the expected timing thereof; expectations regarding MannKind’s ongoing and planned clinical trials and nonclinical studies, including the timing for enrollment for the Phase 2 clinical trial of MNKD-201 in IPF and the expected timing for data readouts from the Phase 1b clinical trial of MNKD-201, and preclinical development of MNKD-701; the potential benefits of Furoscix ReadyFlow Autoinjector and Afrezza Inhalation Powder in pediatrics, if approved; the ADA’s Standards of Care in Diabetes 2026 recommendations for inhaled insulin creating a catalyst for broader adoption; and MannKind being positioned to drive long-term value. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data; risks associated with safety and other complications of our products and product candidates; risks associated with the regulatory review process; risks associated with competition; manufacturing risks; market adoption risks; and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Annual Report on Form 10-K for the year ended December 31, 2025, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Tyvaso DPI is a trademark of United Therapeutics Corporation.
Furoscix is a registered trademark and Furoscix ReadyFlow is a trademark of scPharmaceuticals Inc., a subsidiary of MannKind Corporation.
AFREZZA, MANNKIND, TECHNOSPHERE and V-GO are registered trademarks of MannKind Corporation.
MannKind Contacts:
Investor Relations
Kate Miranda
(617) 921-5461
Email: ir@mnkd.com
Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
Three Months |
|
|
Year |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
(In thousands except per share data) |
|
|||||||||||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Commercial product sales |
|
$ |
50,405 |
|
|
$ |
23,057 |
|
|
$ |
114,137 |
|
|
$ |
82,329 |
|
Collaborations and services |
|
|
27,986 |
|
|
|
26,710 |
|
|
|
106,713 |
|
|
|
100,840 |
|
Royalties |
|
|
33,564 |
|
|
|
27,009 |
|
|
|
128,116 |
|
|
|
102,335 |
|
Total revenues |
|
|
111,955 |
|
|
|
76,776 |
|
|
|
348,966 |
|
|
|
285,504 |
|
Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of goods sold – commercial, excluding amortization of acquired intangible assets |
|
|
13,927 |
|
|
|
4,808 |
|
|
|
26,800 |
|
|
|
17,429 |
|
Cost of revenue – collaborations and services |
|
|
15,746 |
|
|
|
14,796 |
|
|
|
61,160 |
|
|
|
59,173 |
|
Research and development |
|
|
27,588 |
|
|
|
11,138 |
|
|
|
66,348 |
|
|
|
45,893 |
|
Selling, general and administrative |
|
|
58,411 |
|
|
|
23,972 |
|
|
|
144,135 |
|
|
|
94,329 |
|
Amortization of acquired intangible assets |
|
|
3,973 |
|
|
|
— |
|
|
|
3,973 |
|
|
|
— |
|
(Gain) loss on foreign currency transaction |
|
|
(3 |
) |
|
|
(4,433 |
) |
|
|
7,749 |
|
|
|
(3,907 |
) |
Total expenses |
|
|
119,642 |
|
|
|
50,281 |
|
|
|
310,165 |
|
|
|
212,917 |
|
(Loss) income from operations |
|
|
(7,687 |
) |
|
|
26,495 |
|
|
|
38,801 |
|
|
|
72,587 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income, net |
|
|
1,637 |
|
|
|
2,825 |
|
|
|
8,053 |
|
|
|
12,615 |
|
Interest expense on liability for sale of future royalties |
|
|
(3,885 |
) |
|
|
(3,452 |
) |
|
|
(14,449 |
) |
|
|
(16,172 |
) |
Interest expense on financing liability |
|
|
(2,451 |
) |
|
|
(2,467 |
) |
|
|
(9,750 |
) |
|
|
(9,828 |
) |
Impairment of available-for-sale investment |
|
|
— |
|
|
|
— |
|
|
|
(6,409 |
) |
|
|
(1,550 |
) |
Interest expense |
|
|
(7,536 |
) |
|
|
(1,562 |
) |
|
|
(13,830 |
) |
|
|
(11,981 |
) |
Other (expense) income |
|
|
(1,009 |
) |
|
|
— |
|
|
|
(1,009 |
) |
|
|
32 |
|
Gain on bargain purchase |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,259 |
|
Loss on settlement of debt |
|
|
— |
|
|
|
(13,394 |
) |
|
|
— |
|
|
|
(20,444 |
) |
Total other expense |
|
|
(13,244 |
) |
|
|
(18,050 |
) |
|
|
(37,394 |
) |
|
|
(42,069 |
) |
Income before income tax (benefit) expense |
|
|
(20,931 |
) |
|
|
8,445 |
|
|
|
1,407 |
|
|
|
30,518 |
|
Income tax (benefit) expense |
|
|
(4,983 |
) |
|
|
1,023 |
|
|
|
(4,456 |
) |
|
|
2,930 |
|
Net (loss) income |
|
$ |
(15,948 |
) |
|
$ |
7,422 |
|
|
$ |
5,863 |
|
|
$ |
27,588 |
|
Net (loss) income per share – basic |
|
$ |
(0.05 |
) |
|
$ |
0.03 |
|
|
$ |
0.02 |
|
|
$ |
0.10 |
|
Weighted average shares used to compute net (loss) income |
|
|
307,260 |
|
|
|
279,191 |
|
|
|
305,639 |
|
|
|
274,415 |
|
Net (loss) income per share – diluted |
|
$ |
(0.05 |
) |
|
$ |
0.03 |
|
|
$ |
0.02 |
|
|
$ |
0.10 |
|
Weighted average shares used to compute net (loss) income |
|
|
307,260 |
|
|
|
290,631 |
|
|
|
314,112 |
|
|
|
283,844 |
|
_________________________
MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
|
|
December 31, 2025 |
|
|
December 31, 2024 |
|
||
|
|
(In thousands except share |
|
|||||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
74,882 |
|
|
$ |
46,339 |
|
Short-term investments |
|
|
96,464 |
|
|
|
150,917 |
|
Accounts receivable, net |
|
|
38,367 |
|
|
|
11,804 |
|
Inventory |
|
|
35,313 |
|
|
|
27,886 |
|
Prepaid expenses and other current assets |
|
|
46,553 |
|
|
|
31,360 |
|
Total current assets |
|
|
291,579 |
|
|
|
268,306 |
|
Restricted cash |
|
|
745 |
|
|
|
737 |
|
Long-term investments |
|
|
5,012 |
|
|
|
5,482 |
|
Property and equipment, net |
|
|
82,423 |
|
|
|
85,365 |
|
Goodwill |
|
|
67,595 |
|
|
|
1,931 |
|
Developed technology - on-body infusor |
|
|
190,027 |
|
|
|
— |
|
IPR&D - ReadyFlow Formulation |
|
|
129,600 |
|
|
|
— |
|
Other intangible assets |
|
|
5,072 |
|
|
|
5,265 |
|
Other assets |
|
|
20,129 |
|
|
|
26,757 |
|
Total assets |
|
$ |
792,182 |
|
|
$ |
393,843 |
|
|
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS' DEFICIT |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
9,034 |
|
|
$ |
6,792 |
|
Accrued expenses and other current liabilities |
|
|
64,628 |
|
|
|
40,293 |
|
Senior convertible notes – current |
|
|
36,280 |
|
|
|
— |
|
Liability for sale of future royalties – current |
|
|
14,298 |
|
|
|
12,283 |
|
Contingent consideration - current |
|
|
21,132 |
|
|
|
— |
|
Financing liability – current |
|
|
10,328 |
|
|
|
10,062 |
|
Deferred revenue – current |
|
|
15,331 |
|
|
|
12,407 |
|
Total current liabilities |
|
|
171,031 |
|
|
|
81,837 |
|
Liability for sale of future royalties – long term |
|
|
136,985 |
|
|
|
137,362 |
|
Financing liability – long term |
|
|
93,092 |
|
|
|
93,877 |
|
Deferred revenue – long term |
|
|
39,977 |
|
|
|
51,160 |
|
Recognized loss on purchase commitments – long term |
|
|
65,952 |
|
|
|
58,204 |
|
Operating lease liability |
|
|
10,689 |
|
|
|
11,645 |
|
Contingent consideration – long term |
|
|
5,114 |
|
|
|
— |
|
Milestone liabilities |
|
|
2,003 |
|
|
|
2,523 |
|
Term loan |
|
|
318,361 |
|
|
|
— |
|
Senior convertible notes |
|
|
— |
|
|
|
36,051 |
|
Total liabilities |
|
|
843,204 |
|
|
|
472,659 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' deficit: |
|
|
|
|
|
|
||
Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized; |
|
|
— |
|
|
|
— |
|
Common stock, $0.01 par value – 800,000,000 shares authorized; |
|
|
3,078 |
|
|
|
3,029 |
|
Additional paid-in capital |
|
|
3,141,741 |
|
|
|
3,118,865 |
|
Accumulated other comprehensive income |
|
|
115 |
|
|
|
1,109 |
|
Accumulated deficit |
|
|
(3,195,956 |
) |
|
|
(3,201,819 |
) |
Total stockholders' deficit |
|
|
(51,022 |
) |
|
|
(78,816 |
) |
Total liabilities and stockholders' deficit |
|
$ |
792,182 |
|
|
$ |
393,843 |
|
Non-GAAP Measures
To supplement our consolidated financial statements presented under GAAP, we are presenting non-GAAP net income (loss) and non- GAAP net income (loss) per share - basic, which are non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future
cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of its adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non- GAAP financial measures, the non-GAAP financial measures as used by us in this report have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
The following table reconciles our financial measures for net income (loss) and net income (loss) per share ("EPS") for basic weighted average shares as reported in our consolidated statement of operations to a non-GAAP presentation:
|
Three Months |
|
|
Year |
||||||||||||||||||||||||||||
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
||||||||||||||||||||
|
Net Income |
|
|
Basic EPS |
|
|
Net Income |
|
|
Basic EPS |
|
|
Net Income |
|
|
Basic EPS |
|
|
Net Income |
|
|
Basic EPS |
|
|
||||||||
|
(In thousands except per share data) |
|||||||||||||||||||||||||||||||
GAAP reported net (loss) income |
$ |
(15,948 |
) |
|
$ |
(0.05 |
) |
|
$ |
7,422 |
|
|
$ |
0.03 |
|
|
$ |
5,863 |
|
|
$ |
0.02 |
|
|
$ |
27,588 |
|
|
$ |
0.10 |
|
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Stock compensation |
|
6,972 |
|
|
|
0.02 |
|
|
|
5,818 |
|
|
|
0.02 |
|
|
|
24,195 |
|
|
|
0.08 |
|
|
|
21,358 |
|
|
|
0.08 |
|
|
Interest expense on liability for sale of future royalties |
|
3,885 |
|
|
|
0.01 |
|
|
|
3,452 |
|
|
|
0.01 |
|
|
|
14,449 |
|
|
|
0.05 |
|
|
|
16,172 |
|
|
|
0.06 |
|
|
Sold portion of royalty revenue (1) |
|
(3,357 |
) |
|
|
(0.01 |
) |
|
|
(2,701 |
) |
|
|
(0.01 |
) |
|
|
(12,812 |
) |
|
|
(0.04 |
) |
|
|
(10,234 |
) |
|
|
(0.04 |
) |
|
Acquisition-related expenses (2) |
|
6,017 |
|
|
|
0.03 |
|
|
|
— |
|
|
|
— |
|
|
|
9,690 |
|
|
|
0.03 |
|
|
— |
|
|
|
— |
|
|
|
Amortization of intangible assets acquired |
|
3,973 |
|
|
|
0.01 |
|
|
|
— |
|
|
|
— |
|
|
|
3,973 |
|
|
|
0.01 |
|
|
|
— |
|
|
|
— |
|
|
(Gain) loss on foreign currency transaction |
|
(3 |
) |
|
|
— |
|
|
|
(4,433 |
) |
|
|
(0.02 |
) |
|
|
7,749 |
|
|
|
0.03 |
|
|
|
(3,907 |
) |
|
|
(0.01 |
) |
|
Impairment loss on available-for-sale investment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,409 |
|
|
|
0.01 |
|
|
|
1,550 |
|
|
|
0.01 |
|
|
Gain on bargain purchase |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
— |
|
|
|
(5,259 |
) |
|
|
(0.02 |
) |
|
|
Loss on settlement of debt |
|
— |
|
|
|
— |
|
|
|
13,394 |
|
|
|
0.05 |
|
|
— |
|
|
|
— |
|
|
|
20,444 |
|
|
|
0.07 |
|
|
|
Non-GAAP adjusted net income (loss) |
$ |
1,539 |
|
|
$ |
0.01 |
|
|
$ |
22,952 |
|
|
$ |
0.08 |
|
|
$ |
59,516 |
|
|
$ |
0.19 |
|
|
$ |
67,712 |
|
|
$ |
0.25 |
|
|
Weighted average shares used to compute net income (loss) |
|
307,260 |
|
|
|
|
|
|
279,191 |
|
|
|
|
|
|
305,639 |
|
|
|
|
|
|
274,415 |
|
|
|
|
|
||||
_______________________
FAQ
How did MannKind (MNKD) perform financially in Q4 2025?
What were MannKind’s full year 2025 revenues and growth versus 2024?
Was MannKind profitable in 2025 and how did earnings change from 2024?
How much revenue did Furoscix contribute to MannKind in 2025?
How did Afrezza sales trend for MannKind in 2025?
What major pipeline and regulatory milestones does MannKind highlight for 2026?
What is MannKind’s cash and investment position at year-end 2025?
Filing Exhibits & Attachments
2 documentsPress Releases
